Home | Inova Search App - Admin

Project: EveryChild A Registry, Eligibility Screening, Biology and Outcome Study

Submitted by centretek on Sat, 10/15/2022 - 10:29
Read more about Project: EveryChild A Registry, Eligibility Screening, Biology and Outcome Study
A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Participants with DCIS Following Breast Conserving Therapy

Submitted by centretek on Sat, 10/15/2022 - 10:29
Read more about A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Participants with DCIS Following Breast Conserving Therapy
Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN)

Submitted by centretek on Sat, 10/15/2022 - 10:29
Read more about Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN)
Pulmonary Hypertension Association Registry (PHAR)

Submitted by centretek on Sat, 10/15/2022 - 10:29
Read more about Pulmonary Hypertension Association Registry (PHAR)

Summary

The goal of the PHAR is to measure and improve quality of care (including assessing differences in adherence to evidence-based guidelines and establishing benchmarks for health outcomes) while determining the clinical effectiveness, comparative effectiveness, and cost effectiveness of treatment approaches.
A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced

Submitted by centretek on Sat, 10/15/2022 - 10:29
Read more about A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON)

Submitted by centretek on Sat, 10/15/2022 - 10:29
Read more about A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON)
Randomized Phase II/III Trial Of Radiation With High-Dose Cisplatin (100 Mg/M2) Every 3 Weeks vs Radiation With Low-Dose Weekly Cisplatin (40 Mg/M2) For Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (Scchn) (NRG-HN009)

Submitted by centretek on Sat, 10/15/2022 - 10:29
Read more about Randomized Phase II/III Trial Of Radiation With High-Dose Cisplatin (100 Mg/M2) Every 3 Weeks vs Radiation With Low-Dose Weekly Cisplatin (40 Mg/M2) For Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (Scchn) (NRG-HN009)
A Randomized Phase II Study of Brentuximab Vedotin (NSC# 749710) and Crizotinib (NSC# 749005) in Patients with Newly Diagnosed Anaplastic Large Cell Lymphoma (ALCL)IND #117117

Submitted by centretek on Sat, 10/15/2022 - 10:29
Read more about A Randomized Phase II Study of Brentuximab Vedotin (NSC# 749710) and Crizotinib (NSC# 749005) in Patients with Newly Diagnosed Anaplastic Large Cell Lymphoma (ALCL)IND #117117

Summary

A Randomized Phase II Study of Brentuximab Vedotin (NSC# 749710) and Crizotinib (NSC# 749005) in Patients with Newly Diagnosed Anaplastic Large Cell Lymphoma (ALCL)IND #117117
Randomized Phase 2 Trial Evaluating the Addition of the IGF-lR Monoclonal Antibody Ganitumab (AMG479, NSC#750008, IND#120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma

Submitted by centretek on Sat, 10/15/2022 - 10:29
Read more about Randomized Phase 2 Trial Evaluating the Addition of the IGF-lR Monoclonal Antibody Ganitumab (AMG479, NSC#750008, IND#120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma

Summary

Randomized Phase 2 Trial Evaluating the Addition of the IGF-lR Monoclonal Antibody Ganitumab (AMG479, NSC#750008, IND#120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma
A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND#117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (CHL) in Children and Adolescents

Submitted by centretek on Sat, 10/15/2022 - 10:29
Read more about A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND#117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (CHL) in Children and Adolescents